The Margaret and Herman Sokol Institute for Pharmaceutical Life Sciences was established by Montclair State University’s College of Science and Mathematics in 2007 to rapidly advance the critical skills, approaches and research for the development of solutions to global health issues. The Institute supports transdisciplinary research among CSAM faculty and students and academic and industry collaborators in the areas of medicinal chemistry, pharmacology, biochemistry, natural products chemistry, molecular biology, computational sciences, environmental toxicology and pharmacology and emerging technologies such as biomaterials and nanotechnology.
- Montclair State University joins the Open Synthesis NetworkDr. John Siekierka and Dr. David Rotella will now offer graduate and undergraduate students the opportunity to participate in “real” drug discovery for neglected diseases through the Sokol Institute.Tuesday October 9, 2018
The Sokol Institute is uniquely positioned to expand and extend the University’s traditional role in preparing scientists, researchers and technicians for the state’s multi-billion dollar pharmaceutical life sciences industry and rapidly growing biotechnology sector. Promoting a diversity of research programs in the Pharmaceutical Life Sciences that impact human health in general, part of the Institute’s mission strives to bring a global perspective to research regarding disease mechanisms and therapeutic approaches for AIDS, malaria, and other important global issues. The Institute creates advanced experimentation and discovery approaches such as high throughput screening, proteomics, biomaterial platforms and drug analysis technologies accessible to both the College and outside industry community.
The Institute is equipped to help develop advanced graduate and post-doctoral programs in pharmaceutical disciplines such as medicinal chemistry, biochemistry and pharmacology with CSAM. In addition, the Institute establishes technology incubators with various business partners to promote the development of new life sciences technologies and products.
With significant increases in the number of our students majoring in key drug development fields such as chemistry, biochemistry and molecular biology; recruitment of faculty from top academic and industrial institutions around the world; and the active pursuit of significant research into areas including: neglected diseases, oncology, medicinal chemistry, and computational technologies, the Sokol Institute is poised to provide the skilled, highly educated workforce maintaining New Jersey as the pre-eminent location for the global pharmaceutical and medical technology industry.